Interestingly, amongst viable (majority die in utero or postnatally) Roberts Syndrome (RBS) patients, which are homozygous null of ESCO2, they also display reduced SCC and early onset tumor occurrence [41–43]; supporting the fact that reduced SCC is tumor-promoting across species. This evidence concerns the gene ESCO2 and Roberts-SC phocomelia syndrome.